of Gab2 impaired proliferation of MOLM-13 cells compared with noninduced controls (Fig. 1E ). Supporting this, the proportion of cells with lower shRNA expression, indicated by tRFP coexpression, increased over time (Fig. S3C , Supplemental Digital Content, http://links.lww.com/HS/A30). These observations are in line with a study showing similar results in the FLT3-ITD-positive MV4-11 cell line. 5 In addition, we analyzed and correlated Gab2 expression and dependency using the DepMap data explorer with the public 18Q3 expression and CRISPR datasets. 9, 10 Our correlation shows that MOLM-13 and MV4-11, among other AML cell lines, have high Gab2 expression levels and that both cell lines show Gab2 dependency in a CRISPR proliferation screen (Fig. S3F , Supplemental Digital Content, http://links.lww.com/HS/A30). Next, we determined the influence of Gab2 on tyrosine kinase inhibitor (TKI) sensitivity using QZ. Importantly, Gab2 knockdown rendered MOLM-13 cells more sensitive toward QZ (Figs. 1F and S3D and E, Supplemental Digital Content, http://links.lww.com/HS/A30). We previously observed that Gab2 alters TKI sensitivity in the context of chronic myeloid leukemia (CML). 11, 12 Furthermore, others and we previously reported that Gab2 is essential for Bcr-Abl-mediated transformation of murine bone marrow cells in vitro 7 and in vivo. 13 These data hint at a more general phenomenon of Gab2 downstream of hyper-activated kinases. We therefore aimed to investigate whether Gab2 has a similar role for FLT3-mediated transformation. Thus, we infected bone marrow cells from Gab2-proficient, -haploinsufficient, or -deficient mice with bicistronic vectors coexpressing green fluorescent protein (GFP) and wildtype (FLT3-WT) or mutant FLT3 (FLT3-ITD or FLT3-TKD). 14 Gab2 expression levels were validated via Western Blot (Fig. S4A , Supplemental Digital Content, http:// links.lww.com/HS/A30) and comparable infection rates were controlled by flow cytometry (Fig. S4B , Supplemental Digital Content, http://links.lww.com/HS/A30). As expected, FLT3-WT does not harbor oncogenic potential and the infected cells died within a few days after cytokine deprivation regardless of their Gab2 genotype ( Fig. 2A) . By contrast, FLT3-ITD-infected cells survived cytokine independently in a Gab2-proficient or -haploinsufficient background ( Fig. 2A) and GFP-positive cells enriched over time (Fig. 2B) . Strikingly, FLT3-ITD was not able to transform Gab2-deficient cells ( Fig. 2A and B) , indicating an essential role for Gab2 in FLT3-ITD-mutant AML. Flow cytometry data were underlined by microscopy observations (Fig. S4D , Supplemental Digital Content, http://links.lww.com/ HS/A30) and FLT3 expression was validated via Western Blot (Fig. S4C , Supplemental Digital Content, http://links.lww.com/ HS/A30). We also tested the FLT3-TKD mutation D838Y, but none of the cells survived cytokine-independently, regardless of their Gab2 genotype. This finding may be linked to the differences in the clinical outcome of FLT3-ITD-versus FLT3-TKD-positive AMLs, 1 as well as to differences in factorindependent growth in culture and murine bone marrow transplantation models. 14 In accordance with earlier studies, 7, 8 Gab2 was also essential for Bcr-Abl-mediated transformation of murine bone marrow cells ( Fig. 2A and B) . To explore the role of Gab2 in human AML pathology, we stained Gab2 in bone marrow biopsies of AML patients harboring either an FLT3-ITD or an FLT3-TKD mutation ( Fig. 2C and D, Supplementary  Table S1 , Supplemental Digital Content, http://links.lww.com/ HS/A30). Furthermore, we included samples from FLT3-WT/ NPM1-mutant AML to see whether Gab2 expression might be a feature specific to AML driven by constitutively active signaling molecules ( Fig. 2C and D , Supplementary Table S1 , Supplemen-tal Digital Content, http://links.lww.com/HS/A30). Strikingly, we observed a strong Gab2 staining in samples from patients with FLT3-ITD, FLT3-TKD, and NPM1 mutations, respectively (Fig. 2C) , thus supporting a biologically relevant role for Gab2 in FLT3-and NPM1-mutant AML. Additionally, the subcellular localization of Gab2 changed from cytoplasmic, in myeloid cells from healthy controls, to a perinuclear/nuclear appearance in immature myeloid cells and blasts. This phenomenon is in coherence with our previous findings in blasts from CML patients 15 and points toward a role of Gab2 in the nucleus/ perinuclear region. Supporting this, Osawa et al reported the nuclear translocation of Gab1 and identified a nuclear localization signal, 16 which is highly conserved and also present in Gab2, except for one exchange of lysine to arginine that should not affect its function. Despite the different transformation potential of FLT3-ITD and FLT3-TKD mutations, we were not able to detect differences in their Gab2 staining pattern, suggesting that Gab2 might also be important in FLT3-TKD-mutant AML. Furthermore, our observation that FLT3-WT/NPM1-mutant AML cases show a similar Gab2 staining even points toward a more general role of Gab2 in AML.
In summary, our data identify Gab2 as a critical component for the FLT3-ITD-mediated transformation of murine bone marrow cells. Its knockdown impairs proliferation and increases QZ sensitivity in MOLM-13 cells. Finally, we showed that Gab2 is highly expressed in myeloid cells of patients with FLT3-and NPM1-mutant AML compared with healthy controls.
Therefore, our current data invite for further evaluation of Gab2 as a biomarker for TKI sensitivity or even as a new therapeutic target in AML. In addition, our work contributes to the emerging role of Gab2 as an essential signaling hub in various leukemia entities. Beside AML, Gab2 has been described to be critical for the development of CML 7, 11, 13 and more recently also for juvenile myelomonocytic leukemia. 17 Realization of pharmacological implications of the role of Gab2 call for novel approaches, for example, targeting Gab2 protein-protein interactions, 18 as Gab2 has no enzymatic activity.
